Killing of Streptococcus pneumoniae by capsular polysaccharide–specific polymeric IgA, complement, and phagocytes
Authors:
- Edward N. JanoffEJEdward N. Janoff
- Claudine FaschingCFClaudine Fasching
- Jan M. OrensteinJOJan M. Orenstein
- Jeffrey B. RubinsJRJeffrey B. Rubins
- Nancy L. OpstadNONancy L. Opstad
- Agustin P. DalmassoADAgustin P. Dalmasso
Open Access
- 15 October 1999
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 104 (8) , 1139-1147
Abstract
The role of IgA in the control of invasive mucosal pathogens such as Streptococcus pneumoniae is poorly understood. We demonstrate that human pneumococcal capsular polysaccharide–specific IgA initiated dose-dependent killing of S. pneumoniae with complement and phagocytes. The majority of specific IgA in serum was of the polymeric form (pIgA), and the efficiency of pIgA-initiated killing exceeded that of monomeric IgA–initiated killing. In the absence of complement, specific IgA induced minimal bacterial adherence, uptake, and killing. Killing of S. pneumoniae by resting phagocytes with immune IgA required complement, predominantly via the C2-independent alternative pathway, which requires factor B, but not calcium. Both S. pneumoniae–bound IgA and complement were involved, as demonstrated by a 50% decrease in killing with blocking of Fcα receptor (CD89) and CR1/CR3 (CD35/CD11b). However, IgA-mediated killing by phagocytes could be reproduced in the absence of opsonic complement by pre-activating phagocytes with the inflammatory products C5a and TNF-α. Thus, S. pneumoniae capsule–specific IgA may show distinct roles in effecting clearance of S. pneumoniae in the presence or absence of inflammation. These data suggest mechanisms whereby pIgA may serve to control pneumococcal infections locally and upon the pathogen’s entry into the bloodstream.Keywords
This publication has 73 references indexed in Scilit:
- HUMAN COMPLEMENT ACTIVATION VIA THE ALTERNATIVE PATHWAY ON PORCINE ENDOTHELIUM INITIATED BY IgA ANTIBODIESTransplantation, 1995
- Impact of Streptococcus pneumoniae Bacteremia and Human Immunodeficiency Virus Type 1 on Oral Mucosal ImmunityThe Journal of Infectious Diseases, 1995
- Pathogenesis of Pneumococcal InfectionNew England Journal of Medicine, 1995
- Interferon‐mediated transcriptional and post‐transcriptional modulation of complement gene expression in human monocytesEuropean Journal of Biochemistry, 1990
- Anti‐inflammatory activity of human IgA antibodies and their Fabα fragments: inhibition of IgG‐mediated complement activationEuropean Journal of Immunology, 1989
- Complement‐Fixing Properties of Human IgA Antibodies Alternative Pathway Complement Activation by Plastic‐Bound, But Not Specific Antigen‐Bound, IgAScandinavian Journal of Immunology, 1989
- Passive acquired mucosal immunity to group A streptococci by secretory immunoglobulin A.Journal of Experimental Medicine, 1988
- A surface receptor specific for human IgA on group B streptococci possessing the Ibc protein antigen.Journal of Experimental Medicine, 1984
- Biosynthesis of the complement components and the regulatory proteins of the alternative complement pathway by human peripheral blood monocytes.Journal of Experimental Medicine, 1980
- ACTIVITY OF DISSOCIATED AND REASSOCIATED 19S ANTI-γ-GLOBULINSJournal of Experimental Medicine, 1964